

# GOLODIRSEN (VYONDYS 53®) PRESCRIBER ORDER FORM

Patient Name:		Date of Birth:	Gender:
Address:			
Phone:	Height: _____ <input type="checkbox"/> inches <input type="checkbox"/> cm	Weight: _____ <input type="checkbox"/> lbs <input type="checkbox"/> kg	Date weight obtained: _____
<b>Clinical Information</b>			
Primary Diagnosis Description: Duchenne muscular dystrophy (DMD)		ICD-10 Code: G71.01	
Allergies: <input type="checkbox"/> NKDA OR (List):			
<b>Golodirsen (VYONDYS 53®) Prescription</b>			
<b>Golodirsen (VYONDYS 53®) refill as directed x 1 year</b>			
<input type="checkbox"/> Infuse 30 mg/kg IV over 35 to 60 minutes every week (+/- 3 days to allow for patient/nurse scheduling). Dose will be rounded to closest 100 mg. Flush IV tubing with 0.9% Sodium Chloride 10 to 20 mL after each infusion. Prescriber will obtain weight for non-ambulatory patients and provide dose changes to pharmacy as needed. Prescriber will arrange monthly dipstick proteinuria monitoring.			
<input type="checkbox"/> Other: _____			
<b>Ancillary Orders</b>			
<b>Anaphylaxis Kit</b>			
Does this patient require an anaphylaxis kit?			
<input type="checkbox"/> Yes, with 1 <sup>st</sup> dose <input type="checkbox"/> Yes, with all doses			
<ul style="list-style-type: none"><li>▪ Epinephrine 0.3 mg (&gt; 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (&lt; 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN.</li><li>▪ Diphenhydramine 25 mg (&gt; 30 kg) or 1.25 mg/kg (≤ 30 kg – 25mg max per dose) IV or IM; repeat x 1 in 15 min PRN no improvement.</li><li>▪ 0.9% Sodium Chloride 500 mL (&gt; 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis.</li></ul>			
<b>Medication Orders</b>			
<input type="checkbox"/> Lidocaine/prilocaine 2.5%/2.5% (or equivalent) anesthetic cream 30 gm – apply topically 30 min prior to venipuncture or port access as needed for numbing.			
<input type="checkbox"/> Other: _____			
<b>IV Flush Orders</b>			
<ul style="list-style-type: none"><li>• <u>Peripheral</u>: 0.9% Sodium Chloride 2 to 3 mL pre-/post-use.</li><li>• <u>Implanted Port</u>: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use.</li></ul>			
For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. If unable to obtain implanted port access, it is acceptable to establish a peripheral IV access and administer peripherally.			
<b>Lab Orders</b>			
<input type="checkbox"/> Serum cystatin C every 3 months.			
<input type="checkbox"/> No labs ordered at this time.			
<input type="checkbox"/> Other: _____			
Skilled nurse to assess and administer via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year.			
If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.			
<i>I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.</i>			
Prescriber Signature: _____		Date: _____	
<b>Prescriber Information</b>			
Prescriber Name:		Phone:	Fax:
Address:		NPI:	
City, State:	Zip:	Office Contact:	
<b>Fax completed form, insurance information, and clinical documentation to: 410-558-6439</b>			

**CONFIDENTIAL HEALTH INFORMATION:** Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

**Not valid for use for patients residing in Arizona, New York, and Wisconsin**